Collectively, Fgl1 treatment may potentially inhibit critical pro-inflammatory biomarkers of RA through suppression of T cell activity, thereby attenuating the pathological signs of RA disease in the CIA mouse model. The gene discussed is FGL1; the disease is rheumatoid arthritis.